Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
3.540
-0.930 (-20.81%)
At close: Apr 6, 2026, 4:00 PM EDT
3.600
+0.060 (1.69%)
After-hours: Apr 6, 2026, 5:55 PM EDT

Akari Therapeutics, Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-17.3-19.79-10.01-17.75-17.42
Depreciation & Amortization
-0.01000
Asset Writedown & Restructuring Costs
5.18----
Stock-Based Compensation
2.892.251.150.740.31
Other Operating Activities
-0.94-1.56-6.71-5.320.24
Change in Accounts Payable
-15.22-0.94-0.88-0.24
Change in Other Net Operating Assets
0.591.320.071.7-1.74
Operating Cash Flow
-10.57-12.55-16.43-21.5-18.85
Cash Acquisitions
-0.38---
Investing Cash Flow
-0.38---
Short-Term Debt Issued
2.11---
Total Debt Issued
2.11---
Short-Term Debt Repaid
-1.05-1.86---
Total Debt Repaid
-1.05-1.86---
Net Debt Issued (Repaid)
1.05-0.86---
Issuance of Common Stock
10.7611.847.0225.2914.29
Other Financing Activities
1.37----
Financing Cash Flow
13.1710.997.0225.2914.29
Foreign Exchange Rate Adjustments
0-00.010.11-0.14
Net Cash Flow
2.6-1.19-9.413.89-4.69
Free Cash Flow
-10.57-12.55-16.43-21.5-18.85
Free Cash Flow Per Share
-12.56-42.04-134.29-275.54-351.28
Cash Interest Paid
0.10.14---
Levered Free Cash Flow
-10.223.91-16.74-6.04-11.31
Unlevered Free Cash Flow
-9.634.06-16.74-6.04-11.31
Change in Working Capital
-0.46.54-0.870.82-1.98
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q